Date: 2014-07-23
Type of information: Nomination
Compound: chief financial officer, chief strategy officer
Company: Juventas Therapeutics (USA - OH)
Therapeutic area: Cardiovascular diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On July 23, 2014, Juventas Therapeutics, a clinical-stage biotechnology company developing a first-in-class regenerative gene therapy for treatment of heart failure announced adding two industry veterans to its leadership team. Dale Sander has joined as Chief Financial Officer. Dr. Francis Plat will serve in an advisory capacity as Chief Strategy Officer.
- Dale Sander has more than 20 years of executive-level finance experience in the biotechnology sector. Most recently, he was Senior Vice President at a multi-national business service provider where he was responsible for global finance and legal operations, including compliance and risk management for operations encompassing more than 40,000 employees in 15 countries. Prior to that, he served as the Chief Financial Officer for multiple biotechnology companies including Biolex Therapeutics, Maxim Pharmaceuticals, Xtronyx and Tactyl Technologies. In these roles, he completed more than $450 million in private and public financings. In addition, he led operations and corporate development activities. Responsibilities included overseeing manufacturing, IT, legal, human resources, and facilities, as well as identifying commercial and licensing opportunities, and negotiating and completing corporate partnerships and M&A transactions, in the U.S., Asia, Europe, Middle East and South America.
- Francis Plat is a board certified cardiologist with more than 20 years of experience leading cardiovascular product development at multiple global pharmaceutical companies. Most recently, Dr. Plat was a Vice President at Merck Research Laboratories where he served as Worldwide Therapeutic Area Head for their cardiovascular franchise. Prior to Merck, he held senior executive positions at Novartis, BMS and Daiichi Sankyo. During his career, Dr. Plat has been responsible for leading multifunctional research and development teams in the design and implementation of highly-visible pivotal clinical trials in the cardiovascular space and has obtained US and European approval of multiple drugs including Azor®, Effient®, and Brinavess.
Financial terms:
Latest news:
Is general: Yes
